Review
Open access
Oct 2026
CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target
Current evidence supports CLDN18.2 as a candidate biomarker for biomarker-enriched investigation, not as an established therapeutic target in CMA, and proposes a framework centered on lineage reprogramming, antigen enrichment, assay standardization, and therapeutic translation.
Wei Yu, Sheng-Tian Wei, Shi-Qing Wan et al.
· Frontiers in Pharmacology · 0 citations